FDA has issued a draft guidance to help sponsors avoid reaching false conclusions about a drug’s effects in clinical trials with multiple endpoints.
The draft guidance, Multiple Endpoints in Clinical Trials, describes strategies for grouping and ordering endpoints for analysis and...







